1. Home
  2. Research
  3. Research Groups
  4. Multiple Sclerosis

Multiple Sclerosis

2023 Activity indicators

  • 1 European competitive project: IMI (3-TR)
  • 5 national public competitive projects/networks: ISCIII, MICINN
  • 9 private projects led
  • 31 clinical studies led 
  • 2 HR competitive contracts: PADI-FSE & Rio Hortega
  • 28 publications
  • IF: 156.53
  • Q1 publications: 14 (50%)
  • D1 publications: (18%)
  • 1 thesis
  • 2 awards
  • National public agency evaluators: 1 PI
  • Members of editorial committees: 2 PI
  • 1 agreement signed with an international company to finance the determination of oligoclonal IgM bands for third parties.
  • 1 new Spanish patent P202390028 based on European validation EP20382988 protecting predictive biomarkers of autoimmunity for treatment with Alemtuzumab in patients with multiple sclerosis.
  • 1 new European patent application EP23383037.1 for predictive biomarkers of response to ocrelizumab treatment in patients with multiple sclerosis.
  • 1 new intellectual property registration CC-BY-ND-NC with reference 2306134577905 to protect an APP for monitoring multiple sclerosis patients
  • 1 biomarker panel for ultra-sensitive detection of biomarkers, protected by know-how, in use
  • 1 consensus document and 1 document with recommendations
  • 2 visitors hosted and 1 month stay:
    • Dansk Multipel Sklerose Center, Denmark
    • Hospital Virgen Macarena, Seville

Milestones

  1. Discovered role of serum neurofilament light chain in identifying multiple sclerosis patients at risk of rapid disability progression. Optimal treatments for these patients identified. Enric Monreal et al. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs. JAMA Neuro2023 Apr 1;80(4):397-403. DOI: 10.1001/jamaneurol.2023.0010. PMID: 36848127.
  2. An algorithm is described that improves the diagnosis of multiple sclerosis by combining a screening test with automated techniques (quantification of kappa-free light chains) and oligoclonal banding in kappa-negative patients. This test has a sensitivity and specificity of more than 95%. Enric Monreal et al. Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis. Front Immunol. 2023 Oct 25:14:1288169. DOI: 10.3389/fi mmu.2023.1288169. PMID: 37954589.
  3. Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine. Alexander Rodero-Romero et al. Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine. Vaccines (Basel). 2023 Aug 22;11(9):1399. DOI: 10.3390/vaccines11091399. PMID: 37766078.
  4. Responsible for WP6 (multiple sclerosis area) within the European 3TR project for the identification of biomarkers of response to treatment in various autoimmune pathologies. 
  5. Development of the IRYCIS 'Precision Immunological Markers' service, generating new agreements with industry worth over 400,000 euros.

Bibliometrics

  Articles Accum. IF Mean IF Articles Q1 or Q2  % in Q1 or Q2 Articles D1 % in D1
2019 18 64.45 3.58 11 61 0 0
2020 27 110.61 4.10 24 89 3 11
2021 38 315.39 8.30 26 68 10 26
2022 30 151.34 5.04 25 83 1 3
2023 28 156.53 6.52 19 68 5 18
  141 798.31 5.51 105 74 19 13

* Only original articles, editorial material, guidelines and reviews.

Networks and alliances